ArticleNature clinical practice. Oncology2008
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma.
Article in Nature clinical practice. Oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery.Nucleic acids research · 2016Article
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Cancer immunology research · 2015Article
- Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.European journal of radiology · 2015Review
- Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.Human pathology · 2014Article
- A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.Journal of immunology research · 2014Review
- Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Korean journal of radiologyReview
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical investigations of adoptive therapy in solid tumors have primarily focused on CD8(+) cells. A study by Hunder et al. is the first to demonstrate the significance of antigen-specific CD4(+) T cells. An in vitro method was used to treat a patient with metastatic melanoma using autologous CD4(+) cells against NY-ESO-1 (cancer and/or testis antigen 1). The successful adoptive transfer of antigen-specific CD4(+) cells to a patient with metastatic melanoma is not only an important technical accomplishment but also provides increased understanding of tumor immunity. This report demonstrates an impressive persistence of adoptively transferred cells together with durability of clinical response. CD4(+) T cells that target a particular antigen can augment T-cell responses to other tumor-associated targets. These observations underline the importance of ongoing research for effective, non-toxic immune therapies for cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.